We were joined by experts Nick Wildgoose, Nigel Miers, Andy Collier and Haider Mawji in this discussion, where the panel outlined what lies ahead for the future of the Financial Director and Chief Financial Officer role in 2021 and beyond. The panel share decades of experience, whilst covering key topics such as managing costs, cashflow
Investment Director Jill Williams explains how Mercia’s core values have accelerated the Group’s environmental, social and governance (“ESG”) journey and how best practice is vital in moving forward. Our mantra at Mercia is ‘in the regions, from the regions, to the regions’. We passionately believe in making a positive and sustainable regional impact. This is
The top 50 tech businesses in the Midlands from start up to established players included eight within Mercia’s portfolio: Adapttech Birmingham-based Adapttech was founded in 2015 by biomedical engineers Frederico Carpinteiro and Mario Saenz Espinoza. Its INSIGHT tool offers a faster and easier way to fit lower-limb prostheses and monitor patients’ rehabilitation. Staff Circle Leicestershire-based
Over the last six months Mercia has seen investment levels similar to those of the same period last year. Increased levels of co-investment have in part been driven by the introduction of the Future Fund initiative but certainly, capital deployment from Mercia has not slowed down as a result of COVID-19. Mercia’s CIO, Julian Viggars,
Ryan Cawood, CEO and Jocelyne Bath, COO – OXGENE recently outlined OXGENE’s beginnings, how Mercia’s latest investment has helped their biotechnology business successfully scale and their plans post COVID-19. The Life Sciences portfolio collectively accounts for approximately 30% of the portfolio and this interview with Edison’s outlines: Why Mercia invests in the sector
Since 2015 the Northern VCTs have achieved 26 exits from the mature portfolio generating proceeds of £183.2 million and an average return multiple of 2.7x (as at September 2019). It’s a track record which speaks for itself. Today, as part of the Mercia Group (having been acquired from NVM Private Equity in 2019), the
Stuart Holness was Non-executive Chair at Clear Review, which Mercia exited in July of this year. The exit of Clear Review was an 8x on Mercia’s managed funds. Find out more about Stuart, his role at Clear Review and the advice he offers in helping other NEDs during an exit process. How do you typically
As the UK transitions to leave the EU on January 1st 2021, Mercia Asset Management will be hosting numerous webinars on key issues that will impact SMEs. Joining us will be a range of leading subject experts, who will be sharing their knowledge, pragmatic advice and experience to support you and your business to prepare
Life sciences is one of Mercia’s areas of focus and investment expertise. Mercia’s investment track record in the life sciences sector stretches back over 15 years. Today, Mercia manages a portfolio of over 400 businesses through its venture capital, private equity and debt managed funds, of which c 10% by number are in the life
Following Mercia‘s recent life sciences portfolio, three of Mercia’s portfolio CEOs talk about their businesses with Edison: John Burt, CEO of Medherant; John von Benecke, CEO of Locate Bio; and Dr Harry Lamble, CEO of Sense Biodetection. They discuss the support they have received as part of the Mercia family, how their businesses have progressed,